
Cooper Companies (The)
COO · NASDAQ · Health Care
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $11,9 bn
- Div. yield
- <0,1%
- Year to date
- −23,6%
Ratio score
based on 9 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
7 ✓ · 2 — · 0 ✕ · 1 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | 20,9 | 42,7 | 25,1 |
| Forward P/E | 12,7 | — | 16,2 |
| PEG | 3,1 | — | 2,2 |
| P/S | 2,8 | 4,9 | 2,2 |
| EV/EBITDA | 19,4 | 25,3 | 17,3 |
| P/FCF | 17,6 | — | 19,5 |
| P/B | 1,4 | 2,3 | 3,4 |
Industry median — across 33 profitable companies in “Health Care” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 22 analysts
- Buy
- 8
- Hold
- 14
- Sell
- 0
Beat the EPS forecast in 4 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q3 2026 | 1,13 | 1,15 | Up +1,8% |
| Q2 2026 | 1,11 | 1,21 | Up +9,3% |
| Q1 2026 | 1,04 | 1,10 | Up +5,7% |
| Q4 2025 | 1,12 | 1,15 | Up +2,3% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1,07 bn | 1,08 bn | 1,02 bn | 1,07 bn | 1,06 bn | 1,00 bn | 965 m | 1,02 bn | 1,00 bn | 943 m | 932 m | 927 m |
| EPS | 2,24 | −0,40 | 0,66 | 0,42 | 0,49 | 0,44 | 0,52 | 0,59 | 0,52 | 0,44 | 0,41 | 1,70 |
| Margin | 40,6% | −7,2% | 12,8% | 7,9% | 9,3% | 8,7% | 10,8% | 11,5% | 10,4% | 9,4% | 8,7% | 9,1% |
| FCF | 273 m | 96,4 m | 159 m | 150 m | 165 m | 18,1 m | 101 m | 128 m | 119 m | 36,9 m | 4,60 m | 29,2 m |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: purchases $3,18 m (7 people), no sales.
| Name | Amount | Shares | Price |
|---|---|---|---|
| kurzius lawrence erik16 Sep 2026 · open-market purchase | $549 320 | 10 000 | $54,93 |
| rosebrough walter m jr14 Sep 2026 · open-market purchase | $162 870 | 3 000 | $54,29 |
| kurzius lawrence erik14 Sep 2026 · open-market purchase | $539 150 | 10 000 | $53,92 |
| keel paul a11 Sep 2026 · open-market purchase | $249 999 | 4 701 | $53,18 |
| rosebrough walter m jr11 Sep 2026 · open-market purchase | $378 770 | 7 000 | $54,11 |
| lucchese cynthia l22 Dec 2025 · open-market purchase | $149 963 | 1 784 | $84,06 |
| rivas maria18 Dec 2025 · open-market purchase | $82 130 | 1 000 | $82,13 |
| kurzius lawrence erik17 Dec 2025 · open-market purchase | $165 000 | 2 000 | $82,50 |
| sheffield holly r16 Dec 2025 · open-market purchase | $99 323 | 1 230 | $80,75 |
| white albert g iii16 Dec 2025 · open-market purchase | $808 000 | 10 000 | $80,80 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Health Care
- Exchange
- NASDAQ
- Country
- US
- IPO date
- 21 Jan 1983
- Website
- www.coopercos.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- 2 Dec 2026, after close
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
ALGNAlign Technology | $165,98 | 89★★★★★★★★★★would consider | 24,1 | +4,4% | 11,8% |
DVADaVita | $174,22 | 72★★★★★★★★★would consider | 11,9 | +6,4% | 6,5% |
BAXBaxter International | $25,54 | 38★★★★★★★would not consider | — | +5,3% | −6,2% |
UHSUniversal Health Services | $197,80 | 78★★★★★★★★★would consider | 7,8 | +8,0% | 8,0% |
PODDInsulet Corporation | $145,29 | 89★★★★★★★★★★would consider | 24,7 | +26,5% | 13,4% |
Ratio — a score by our methodology, not an investment recommendation.




